arrow
P

P. Connor Johnson

mass general brig ham cancer institute
H指数:22
被引数:1,740

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas

肌肉和脂肪组织指数与侵袭性淋巴瘤临床结局的探索性关联研究

Cancer
IF5.1
2026-02-110
PRE
Ruxolitinib for Ciltacabtagene Autoleucel–Associated Refractory Diarrhea

鲁索利替尼用于cilta-cabtagene autoleucel相关的难治性腹泻

Blood
IF23.1
2026-01-290
PRE
Clinical Presentation, Management and Outcome of Tumor inflammation-associated neurotoxicity (TIAN) in CNS lymphoma treated with CD19-CAR T-cell therapy

肿瘤炎症相关神经毒性(TIAN)在经CD19-CAR T细胞疗法治疗的CNS淋巴瘤中的临床表现、管理与转归

2025-11-010
OAAI
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma

同步系统性及中枢神经系统弥漫大B细胞淋巴瘤的治疗与预后回顾性研究

2025-11-010
OAAI
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study

HH2853(一种新型EZH1/2双抑制剂)在难治性实体瘤或非霍奇金淋巴瘤患者中的安全性与有效性:一项I期研究

2025-08-070
OA
Clinical presentation, management and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy

TIAN的临床表现、管理及CD19-CAR T细胞治疗下在中枢神经系统淋巴瘤中的结局

Blood
IF23.1
2025-07-170
PRE
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)—Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma

5-5-5 ABRT(5周内进行最多5次分割,每次分割剂量为5 Gy的自适应桥接放疗)——人工智能进入CAR(-T)(嵌合抗原受体-T)治疗复发/难治性大B细胞淋巴瘤领域

2025-04-030
PRE
Corrigendum to Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T-Cell Therapy Transplantation and Cellular Therapy, 30 (2024) 452 - 453

勘误:生活质量与预后认知在接收嵌合抗原受体T细胞疗法患者照护者中的研究,《移植与细胞疗法》,30(2024)452-453

2025-04-030
PRE
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy

老年侵袭性淋巴瘤患者接受化疗免疫疗法后的纵向患者报告结局

2025-02-190
PRE
Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies

接受嵌合抗原受体T细胞疗法的成年患者的长期认知结果

2025-01-010
PRE
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
2024-11-141
OAAI